NEW YORK (GenomeWeb News) — The American Society of Clinical Oncology recommends using Genomic Health’s Oncotype DX breast cancer assay, according to an updated set of guidelines for using breast cancer tumor markers, the company said today.
Oncotype DX is used to predict the likelihood of disease recurrence and whether a node-negative, estrogen-receptor positive tumor will respond to chemotherapy. In its updated guidelines, ASCO recommends using the test and “differentiated it as an optimal tool for breast cancer treatment selection," Steve Shak, chief medical officer at Genomic Health, said in a statement.
Genomic Health said ASCO included the test in its updated clinical practice guidelines based on “multiple independent clinical studies involving more than 2,600 breast cancer patients,” including studies published in the New England Journal of Medicine and in the Journal of Clinical Oncology.
These guidelines, which serve as “a guide for doctors and outline appropriate methods of treatment,” were published online today in the Journal of Clinical Oncology and will appear in the journal's Nov. 20 print edition, the company added.